多发性骨髓瘤骨病的机制研究及治疗进展

doi:10.11904/j.issn.1002-3070.2017.03.011

Abstract

Abstract: Multiple myeloma is a more common malignant disease in blood medicine,which is characterized by hyper-proliferation and accumulation of malignant plasma cells in the bone marrow,resulting in a large number of monoclonal immunoglobulins and their fragments,leading to damage to the terminal organs.Of which about 80% of patients have multiple myeloma bone diseases(MBD),which seriously affected the quality of life and prognosis of patients.We have found that the main cause of MBD are contributed to inhibition of osteoblasts,activation of osteoclast and affecting the occurrence by a variety of cytokines and pathways.This article will review and introduce the occurrence and development of MBD related to the latest factors and treatment.

Key words: Multiple myeloma, Myeloma bone disease, Osteoblast, Osteoclast

CLC Number:

R733.3

LI Wenjun,GUO Yanqiu,GAO Yujuan,SU Yanhua. Advarces in mechanism and treatment of multiple myeloma bone disease[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 246-249.

References

1 Eda H,Santo L,David Roodman G,et al.Bone disease in multiple myeloma[J].Cancer Treat Res,2016,169:251-270.
2 Bonewald L.The amazing osteocyte[J].Journal of Bone and Mineral Research,2011,26(2):229-238.
3 Yamagishi T,Kawashima H,Ogose A,et al.Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary bone tumors[J].PLoS One,2016,10;11(5):e0154680.
4 Kushlinskiǐ NE,Timofeev IuS,Gershteǐn ES,et al.Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor[J].Vopr Onkol,2014,60(4):413-421.
5 Walker RE,Lawson MA,Buckle CH,et al.Myeloma bone disease:pathogenesis,current treatments and future targets[J].British Medical Bulletin,2014,111(1):117-138.
6 Colombo M,Mirandola L,Platonova N,et al.Notch-directed microenvironment reprogramming in myeloma:a single path to multiple outcomes[J].Leukemia,2013,27(5):1009-1018.
7 Yin L,Velazquez OC,Liu ZJ.Notch signaling:emerging molecular targets for cancer therapy[J].Biochemical Pharmacology,2010,80(5):690-701.
8 Colombo M,Galletti S,Garavelli S,et al.Notch signaling deregulation in multiple myeloma:A rational molecular target[J].Oncotarget,2015,6(29):26826-26840.
9 Colombo M,Thümmler K,Mirandola L,et al.Notch signaling drives multiple myeloma induced osteoclastogenesis[J].Oncotarget,2014,5(21):10393-10406.
10 Zanotti S,Smerdelramoya A,Stadmeyer L,et al.Notch inhibits osteoblast differentiation and causes osteopenia[J].Endocrinology,2008,149(8):3890-3899.
11 Asano J,Nakano A,Oda A,et al.The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells[J].Leukemia,2011,25(7):1182-1188.
12 Hiasa M,Teramachi J,Oda A,et al.Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma[J].Leukemia,2015,29(1):207-217.
13 Reya T,Clevers H.Wnt signalling in stem cells and cancer[J].Nature,2005,434(7035):843-850.
14 Kestler HA,Kühl M.From individual Wnt pathways towards a Wnt signalling network[J].Philos Trans R Soc Lond B Biol Sci,2008,363(1495):1333-1347.
15 Rachner TD,Gbel A,Benad-Mehner P,et al.Dickkopf-1 as a mediator and novel target in malignant bone disease[J].Cancer Letters,2014,346(2):172-177.
16 Takahashi N,Maeda K,Ishihara A,et al.Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals[J].Front Biosci,2011,16:21-30.
17 Sottnik JL,Hall CL,Zhang J,et al.Wnt and Wnt inhibitors in bone metastasis[J].Bonekey Rep,2012,1:101.
18 Delgado-Calle J,Sato AY,Bellido T.Role and mechanism of action of sclerostin in bone[J].Bone,2017,96:29-37.
19 Ghali O,Chauveau C,Hardouin P,et al.TNF-alpha′s effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression[J].J Bone Miner Res,2010,25(7):1616-1626.
20 Chawla S,Henshaw R,Seeger L,et al.Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone:interim analysis of an open-label,parallel-group,phase 2 study[J].Lancet Oncology,2013,14(9):901-908.
21 Wang JH,Zhang Y,Li HY,et al.Dickkopf-1 negatively regulates the expression of osteoprotegerin,a key osteoclastogenesis inhibitor,by sequestering Lrp6 in primary and metastatic lytic bone lesions[J].Medicine,2016,95(24):e3767.
22 Ri M.Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy[J].Rinsho Ketsueki,2016,57(5):537-545.
23 翁翔,顾超,翟丽娜,等.硼替佐米在多发性骨髓瘤治疗中的应用[J].中国肿瘤,2014,23(8):674-679.
24 Anderson G,Gries M,Kurihara N,et al.Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1[J].Blood,2006,107(8):3098-105.
25 Wang J,Guo H,Zhou X.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients[J].Onco Targets Ther,2015,8:1277-1284.

[1]	LI Lin,MAO Chaoming,ZHOU Jianming,GAO Jianqing. Imaging performance of ¹⁸F-FDG PET-CT on patients with multiple myeloma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 222-227.
[2]	ZHAO Yu,ZHU Xiaoting,WANG Yinan. The role and mechanisms of ω-3 polyunsaturated fatty acids in inducing cell apoptosis and anti-proliferation in multiple myeloma [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 516-522.
[3]	CAO Meilin, XU Yanli, ZHANG Lei. Multiple myeloma after chemotherapy secondary to acute myeloid leukemia:a case report and literature review [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 536-539.
[4]	WANG Yan,LIU Aichun. The advance in the treatment of multiple myeloma [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(2): 183-187.

Advarces in mechanism and treatment of multiple myeloma bone disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments